Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ocrelizumab

Brand: Ocrevus®
NICE TA: 533
Indication: Treating relapsing–remitting multiple sclerosis
Disease category: Immune system and Malignant Disease
Commissioning responsibility: NHSE
PbR excluded: Yes

Background

Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if:
• alemtuzumab is contraindicated or otherwise unsuitable and
• the company provides ocrelizumab according to the commercial arrangement.
This recommendation is not intended to affect treatment with ocrelizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA 533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red